| Literature DB >> 30022792 |
Guannan Li1, Xin Wang1, Xiuwei Wang2, Zhen Guan2, Jin Guo2, Fang Wang2, Jianzhao Zhang1, Bo Niu2, Ting Zhang2, Jianhua Wang2, Jian Yang1.
Abstract
BACKGROUND DNA Base Excision Repair Gene-DNA LigaseIII (LIG3) is an important repair gene in the repair pathway and plays an important role in maintaining the integrity of mitochondria. Rs1052536 and rs3135967 polymorphisms of the gene are associated with lung cancer, keratoconus, and Fuchs endothelial corneal dystrophy. There is no previously published report on the relationship between the polymorphisms and neural tube defects (NTDs). MATERIAL AND METHODS Mass ARRAY iPLEX was used to determine the distribution of the polymorphisms in the case group of 108 NTD pregnant women and a control group of 233 normal healthy pregnant women to examine the relevance of their polymorphisms and NTD occurrence. RESULTS The homozygotes of rs1052536 TT were associated with an increased risk for NTDs than CC (P=0.014, OR=2.31, 95%CI [1.17-4.54]), and variants of rs1052536 T were associated with an increased risk of NTDs (P=0.024, OR=1.50, 95%CI [1.06-2.13]). The stratified analysis showed that TT genotype of rs1052536 increased the risk of anencephaly (P=0.016, OR=2.69, 95%CI [1.18-6.10]) and the T allele significantly increased the risk of cranial NTDs (P=0.033, OR=1.56, 95%CI [1.04-2.35]). CONCLUSIONS Rs1052536 in LIG3 gene might be a potential genetic risk factor in a high-risk area of NTDs in China.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30022792 PMCID: PMC6067017 DOI: 10.12659/MSM.907492
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
The primers and UEP sequences.
| SNP | The primers and UEP sequences | |
|---|---|---|
| rs1052536 | F: | 5′-ACGTTGGATGCATTCCCCCTATACTGTGTC-3′ |
| R: | 5′-ACGTTGGATGCAGGCCATACTCTCCTTTAC-3′ | |
| UEP: | 5′-CATACTCTCCTTTACCATACTA-3′ | |
| rs3135967 | F: | 5′-ACGTTGGATGTTTAACCTCTATCGCAGCGG-3′ |
| R: | 5′-ACGTTGGATGTAATAATCTCTGTCTGGCCC-3′ | |
| UEP: | 5′-GTCTGGCCCAGGTAACTA-3′ | |
The characteristics of the study participants.
| Characteristics | Case (n=108) | Control (n=233) | |
|---|---|---|---|
| Age (year) | |||
| <20 | 6 (6.1) | 8 (3.6) | 0.063 |
| 20–29 | 81 (81.8) | 157 (71.4) | |
| ≥29 | 12 (12.1) | 52 (24.0) | |
| Educational level | |||
| <High school graduation | 93 (86.1) | 180 (81.8) | 0.207 |
| ≥High school graduation | 15 (13.9) | 40 (18.2) | |
| Gravidity (n) | |||
| 1 | 50 (50.0) | 95 (41.7) | 0.218 |
| 2 | 28 (28.0) | 86 (37.7) | |
| ≥3 | 22 (22.0) | 47 (20.6) | |
| Parity(n) | |||
| 0 | 48 (44.9) | 72 (35.5) | 0.169 |
| 1 | 46 (43.0) | 93 (45.8) | |
| ≥2 | 13 (12.1) | 38 (18.7) | |
| Periconceptional folic acid use | |||
| No | 102 (96.2) | 220 (97.3) | 0.402 |
| Yes | 4 (3.8) | 6 (2.7) | |
| Gestational week | |||
| <21 | 51 (56.0) | 162 (72.0) | 0.012 |
| 21–29 | 26 (28.6) | 47 (20.9) | |
| ≥30 | 14 (15.4) | 16 (7.1) |
Percentages may not equal 100 because of rounding;
Values are mean ±SD, t test was used to calculate the P values;
χ2 test was used to calculate P values;
“Periconceptional”refers to the month before conception and the first 3 months after conception.
The total numbers may not equal to 108/233 because of loss of follow-up of subjects and incomplete registration information.
Figure 1Direct sequencing results of rs1052536.
Figure 2Direct sequencing results of rs3135967.
The Hardy-Weinberg equilibrium for case and control of the polymorphisms.
| SNPs | Case/Control | Genotypes | Observed ( | Expected ( | |
|---|---|---|---|---|---|
| rs1052536 | Case | C/C | 53 (50.00%) | 45 (42.45%) | 0.057 |
| C/T | 32 (30.19%) | 48 (45.28%) | |||
| T/T | 21 (19.81%) | 13 (12.27%) | |||
| Control | C/C | 128 (57.14%) | 123 (54.91%) | 0.31 | |
| C/T | 74 (33.04%) | 86 (38.39%) | |||
| T/T | 22 (9.82%) | 15 (6.70%) | |||
| rs3135967 | Case | A/A | 54 (50.47%) | 52 (48.60%) | 0.82 |
| G/A | 41 (38.32%) | 45 (42.06%) | |||
| G/G | 12 (11.21%) | 10 (9.35%) | |||
| Control | A/A | 127 (54.51%) | 124 (53.22%) | 0.59 | |
| G/A | 84 (36.05%) | 92 (39.48%) | |||
| G/G | 22 (9.44%) | 17 (7.30%) |
The total numbers may not equal to 108/233 because of unqualified DNA samples.
Distribution of genotypes and odds ratios (OR) in rs1052536 and rs3135967.
| SNP | Genotype/Allele | Case ( | Control ( | OR (95%CI) | ||
|---|---|---|---|---|---|---|
| rs3135967 | Genotype | A/A | 54 | 127 | 1.00 | |
| G/A | 41 | 84 | 1.15 (0.70–1.88) | 0.58 | ||
| G/G | 12 | 22 | 1.28 (0.59–2.78) | 0.53 | ||
| Allele | A | 149 | 338 | 1.00 | ||
| G | 65 | 128 | 1.15 (0.81–1.64) | 0.44 | ||
| rs1052536 | Genotype | C/C | 53 | 128 | 1.00 | |
| C/T | 32 | 74 | 1.04 (0.62–1.76) | 0.87 | ||
| T/T | 21 | 22 | 2.31 (1.17–4.54) | 0.01 | ||
| Allele | C | 138 | 330 | 1.00 | ||
| T | 74 | 118 | 1.50 (1.06–2.13) | 0.02 | ||
The total numbers may not equal to 108/233 because of unqualified DNA samples.
Distribution of genotypes and odds ratios of rs1052536 in the three subgroups.
| NTD subgroups | Genotype/Allele | Case | Control | OR (95%CI) | |
|---|---|---|---|---|---|
| Anencephaly | CC | 26 | 128 | 1.00 | |
| CT | 20 | 74 | 1.33 (0.70–2.55) | 0.39 | |
| TT | 12 | 22 | 2.69 (1.18–6.10) | 0.016 | |
| C | 72 | 330 | 1.00 | ||
| T | 44 | 118 | 1.71 (1.11–2.63) | 0.014 | |
| Spina Bifida | CC | 21 | 128 | 1.00 | |
| CT | 10 | 74 | 0.82 (0.37–1.84) | 0.64 | |
| TT | 8 | 22 | 2.22 (0.87–5.63) | 0.09 | |
| C | 52 | 330 | 1.00 | ||
| T | 26 | 118 | 1.40 (0.84–2.34) | 0.20 | |
| Encephalocele | CC | 6 | 128 | 1.00 | |
| CT | 2 | 74 | 0.58 (0.11–2.93) | 0.50 | |
| TT | 1 | 22 | 0.97 (0.11–8.45) | 0.98 | |
| C | 14 | 330 | 1.00 | ||
| T | 4 | 118 | 0.80 (0.25–2.48) | 0.70 |
Distribution of genotypes and odds ratios of rs3135967 in the three subgroups.
| NTD subgroups | Genotype/Allele | Case | Control | OR (95%CI) | |
|---|---|---|---|---|---|
| Anencephaly | AA | 26 | 127 | 1.00 | |
| GA | 26 | 84 | 1.15 (0.88–2.78) | 0.18 | |
| GG | 5 | 22 | 1.11 (0.39–3.20) | 0.85 | |
| A | 78 | 338 | 1.00 | ||
| G | 36 | 128 | 1.22 (0.78–1.90) | 0.38 | |
| Spina Bifida | AA | 21 | 127 | 1.00 | |
| GA | 13 | 84 | 0.94 (0.45–1.97) | 0.86 | |
| GG | 7 | 22 | 1.92 (0.73–5.07) | 0.18 | |
| A | 55 | 338 | 1.00 | ||
| G | 27 | 128 | 1.30 (0.78–2.14) | 0.31 | |
| Encephalocele | AA | 7 | 127 | 1.00 | |
| GA | 2 | 84 | 0.43 (0.09–2.13) | 0.29 | |
| GG | 0 | 22 | |||
| A | 16 | 338 | 1.00 | ||
| G | 2 | 128 | 0.33 (0.08–1.46) | 0.18 |
Distribution of genotypes and odds ratios of rs1052536 in cranial NTDs subgroup and controls.
| Genotype/Allele | Cranial NTDs ( | Control ( | OR (95%CI) | |
|---|---|---|---|---|
| CC | 32 (47.8) | 128 (57.1) | 1.00 | |
| CT | 22 (32.8) | 74 (33.0) | 1.19 (0.64–2.20) | 0.193 |
| TT | 13 (19.4) | 22 (9.8) | 2.36 (1.08–5.20) | 0.029 |
| CT+TT | 35 (52.2) | 96 (42.9) | 1.46 (0.84–2.52) | 0.18 |
| C | 86 (64.2) | 330 (73.7) | 1.00 | |
| T | 48 (35.8) | 118 (26.3) | 1.56 (1.04–2.35) | 0.033 |
Distribution of genotypes and odds ratios of rs3135967 in cranial NTDs subgroup and controls.
| Genotype/Allele | Cranial NTDs ( | Control ( | OR (95%CI) | |
|---|---|---|---|---|
| AA | 33 (50.0) | 127 (54.5) | 1.00 | |
| GA | 28 (42.4) | 84 (36.1) | 1.28 (0.72–2.28) | 0.40 |
| GG | 5 (8.2) | 22 (9.4) | 0.88 (0.31–2.48) | 0.80 |
| GA+GG | 33 (50.0) | 106 (45.5) | 1.20 (0.69–2.07) | 0.52 |
| A | 94 (71.2) | 338 (72.5) | 1.00 | |
| G | 38 (28.8) | 128 (27.5) | 1.07 (0.70–1.64) | 0.77 |
Genotype distribution and allele frequencies of rs1052536 polymorphism in normal population of different races.
| Population | n | Genotype ( | Allele ( | |||||
|---|---|---|---|---|---|---|---|---|
| CC | CT | TT | C | T | ||||
| Chinese (Shanxi) | 224 | 128 (57.1) | 74 (33.0) | 22 (9.8) | 330 (73.7) | 118 (26.3) | ||
| CHB | 136 | 71 (52.2) | 51 (37.5) | 14 (10.3) | 0.645 | 193 (71.0) | 79 (29.0) | 0.430 |
| CHD | 109 | 55 (50.5) | 47 (43.1) | 7 (6.4) | 0.164 | 157 (72.0) | 61 (28.0) | 0.654 |
| JPT | 113 | 72 (63.7) | 39 (34.5) | 2 (1.8) | 0.024 | 183 (81.0) | 43 (19.0) | 0.036 |
| CEU | 112 | 24 (21.4) | 64 (57.1) | 24 (21.4) | <0.001 | 112 (50.0) | 112 (50.0) | <0.001 |
| MEX | 57 | 22 (38.6) | 28 (49.1) | 7 (12.3) | 0.040 | 72 (63.2) | 42 (36.8) | 0.027 |
| ASW | 57 | 37 (64.9) | 19 (33.3) | 1 (1.8) | 0.130 | 93 (81.6) | 21 (18.4) | 0.080 |
CHB – Han Chinese in Beijing, China; CHD – Chinese in Metropolitan Denver, Colorado; JPT – Japanese in Tokyo, Japan; CEU – Utah residents with Northern and Western European ancestry from the CEPH collection; MEX – Mexican ancestry in Los Angeles, California; ASW – African ancestry in Southwest USA.
Genotype distribution and allele frequencies of rs3135967 polymorphism in normal population of different races.
| Population | n | Genotype ( | Allele ( | |||||
|---|---|---|---|---|---|---|---|---|
| AA | AG | GG | A | G | ||||
| Chinese (Shanxi) | 233 | 128 (54.5) | 84 (34.1) | 22 (9.8) | 338 (72.5) | 118 (27.5) | ||
| CHB | 137 | 71 (51.8) | 52 (38.0) | 14 (10.2) | 0.880 | 194 (70.8) | 79 (29.2) | 0.613 |
| CHD | 109 | 55 (50.5) | 47 (43.1) | 7 (6.4) | 0.369 | 157 (72.0) | 61 (28.0) | 0.889 |
| JPT | 113 | 72 (80.9) | 39 (34.5) | 2 (1.8) | 0.022 | 183 (81.0) | 43 (19.0) | 0.016 |
| CEU | 113 | 22 (19.5) | 64 (56.6) | 27 (23.9) | <0.001 | 108 (47.8) | 118 (52.2) | <0.001 |
| MEX | 57 | 19 (33.3) | 29 (50.9) | 9 (15.8) | 0.015 | 67 (58.8) | 47 (41.2) | 0.004 |
| ASW | 57 | 37 (64.9) | 19 (33.3) | 1 (1.8) | 0.112 | 93 (81.6) | 21 (18.4) | 0.048 |
CHB – Han Chinese in Beijing, China; CHD – Chinese in Metropolitan Denver, Colorado; JPT – Japanese in Tokyo, Japan; CEU – Utah residents with Northern and Western European ancestry from the CEPH collection; MEX – Mexican ancestry in Los Angeles, California; ASW – African ancestry in Southwest USA.
Figure 3The results of the Haploview software analysis.
Haplotype analysis of rs1052536 and rs3135967*.
| Haplotype | Case (freq) | Control (freq) | Fisher’s | Pearson’s | OR (95%CI) |
|---|---|---|---|---|---|
| C/A | 135.89 (0.647) | 325.99 (0.728) | 0.034941 | 0.034911 | 0.683 (0.479–0.974) |
| C/G | 2.11 (0.010) | 4.01 (0.009) | – | – | – |
| T/A | 14.11 (0.067) | 1.01 (0.002) | – | – | – |
| T/G | 57.89 (0.276) | 116.99 (0.261) | 0.687774 | 0.687774 | 1.079 (0.745–1.561) |
SHEsis (); All those frequency<0.03 will be ignored in analysis.